The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment-Global Market Insights and Sales Trends 2024
Synopsis
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment market size is expected to reach US$ 380.6 million by 2029, growing at a CAGR of 3.4% from 2023 to 2029. The market is mainly driven by the significant applications of Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment in various end use industries. The expanding demands from the Hospitals, Diagnostic Centres, Clinics and Retail Pharmacies, are propelling Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Stem Cell Therapy segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment covered in this report include GNT Pharma, Amkor Pharma, Synthetic Biologics, Mitsubishi Tanabe Pharma, Avicena and Sanofi, etc.
The global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GNT Pharma
Amkor Pharma
Synthetic Biologics
Mitsubishi Tanabe Pharma
Avicena
Sanofi
Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment market, Segment by Type:
Chemotherapy
Stem Cell Therapy
Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment market, by Application
Hospitals
Diagnostic Centres
Clinics
Retail Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Amyotrophic lateral sclerosis (ALS) is also known as Lou Gehrig’s disease or Maladie De Charcot, it is a neurological disease that causes nerve cells to gradually break down and die.
The cause is not known in 90% to 95% of cases. The remaining 5–10% of cases are inherited from a person's parents. About half of these genetic cases are due to one of two specific genes. The underlying mechanism involves damage to both upper and lower motor neurons. The diagnosis is based on a person's signs and symptoms, with testing done to rule out other potential causes.
The global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment market size is expected to reach US$ 380.6 million by 2029, growing at a CAGR of 3.4% from 2023 to 2029. The market is mainly driven by the significant applications of Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment in various end use industries. The expanding demands from the Hospitals, Diagnostic Centres, Clinics and Retail Pharmacies, are propelling Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment market. Chemotherapy, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Stem Cell Therapy segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment covered in this report include GNT Pharma, Amkor Pharma, Synthetic Biologics, Mitsubishi Tanabe Pharma, Avicena and Sanofi, etc.
The global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GNT Pharma
Amkor Pharma
Synthetic Biologics
Mitsubishi Tanabe Pharma
Avicena
Sanofi
Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment market, Segment by Type:
Chemotherapy
Stem Cell Therapy
Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment market, by Application
Hospitals
Diagnostic Centres
Clinics
Retail Pharmacies
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment
1.1 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Overview
1.1.1 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Product Scope
1.1.2 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Status and Outlook
1.2 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size by Region (2018-2029)
1.4 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Historic Market Size by Region (2018-2023)
1.5 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size (2018-2029)
1.6.1 North America Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size (2018-2029)
1.6.2 Europe Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size (2018-2029)
1.6.3 Asia-Pacific Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size (2018-2029)
1.6.4 Latin America Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size (2018-2029)
1.6.5 Middle East & Africa Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size (2018-2029)
2 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market by Type
2.1 Introduction
2.1.1 Chemotherapy
2.1.2 Stem Cell Therapy
2.2 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Historic Market Size by Type (2018-2023)
2.2.2 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue Breakdown by Type (2018-2029)
3 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Overview by Application
3.1 Introduction
3.1.1 Hospitals
3.1.2 Diagnostic Centres
3.1.3 Clinics
3.1.4 Retail Pharmacies
3.2 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Historic Market Size by Application (2018-2023)
3.2.2 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue Breakdown by Application (2018-2029)
4 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Competition Analysis by Players
4.1 Global Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment as of 2022)
4.3 Date of Key Players Enter into Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market
4.4 Global Top Players Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Headquarters and Area Served
4.5 Key Players Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Product Solution and Service
4.6 Competitive Status
4.6.1 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 GNT Pharma
5.1.1 GNT Pharma Profile
5.1.2 GNT Pharma Main Business
5.1.3 GNT Pharma Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Products, Services and Solutions
5.1.4 GNT Pharma Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue (US$ Million) & (2018-2023)
5.1.5 GNT Pharma Recent Developments
5.2 Amkor Pharma
5.2.1 Amkor Pharma Profile
5.2.2 Amkor Pharma Main Business
5.2.3 Amkor Pharma Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Products, Services and Solutions
5.2.4 Amkor Pharma Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue (US$ Million) & (2018-2023)
5.2.5 Amkor Pharma Recent Developments
5.3 Synthetic Biologics
5.3.1 Synthetic Biologics Profile
5.3.2 Synthetic Biologics Main Business
5.3.3 Synthetic Biologics Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Products, Services and Solutions
5.3.4 Synthetic Biologics Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue (US$ Million) & (2018-2023)
5.3.5 Mitsubishi Tanabe Pharma Recent Developments
5.4 Mitsubishi Tanabe Pharma
5.4.1 Mitsubishi Tanabe Pharma Profile
5.4.2 Mitsubishi Tanabe Pharma Main Business
5.4.3 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Products, Services and Solutions
5.4.4 Mitsubishi Tanabe Pharma Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue (US$ Million) & (2018-2023)
5.4.5 Mitsubishi Tanabe Pharma Recent Developments
5.5 Avicena
5.5.1 Avicena Profile
5.5.2 Avicena Main Business
5.5.3 Avicena Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Products, Services and Solutions
5.5.4 Avicena Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue (US$ Million) & (2018-2023)
5.5.5 Avicena Recent Developments
5.6 Sanofi
5.6.1 Sanofi Profile
5.6.2 Sanofi Main Business
5.6.3 Sanofi Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Products, Services and Solutions
5.6.4 Sanofi Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Revenue (US$ Million) & (2018-2023)
5.6.5 Sanofi Recent Developments
6 North America
6.1 North America Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Dynamics
11.1 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Industry Trends
11.2 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Drivers
11.3 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Challenges
11.4 Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease) Treatment Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
